Straight to phase 3...Australias best cancer cure to...

Straight to phase 3...Australias best cancer cure to date

http://www.progen.com.au/prs/progen_final%20phase2%20data_15-apr-07_FINAL%20appendix.pdf

"Generally, the most value uplift one would normally get would be on completion of phase 2 trials," says Wald.

"That's when you've taken out most of the technical risk: the first time you know it works in the target population. If you really want to be a successful investor you've got to have a good idea as to the potential risks of the product not working in humans, or an idea of its potential side effects." Wald calls this "the inflexion point for risk/reward".